Wall Street analysts predict that Idera Pharmaceuticals Inc (NASDAQ:IDRA) will announce earnings of ($0.34) per share for the current quarter, Zacks Investment Research reports. Zero analysts have made estimates for Idera Pharmaceuticals’ earnings. The lowest EPS estimate is ($0.41) and the highest is ($0.21). Idera Pharmaceuticals posted earnings of ($0.45) per share during the same quarter last year, which would suggest a positive year-over-year growth rate of 24.4%. The firm is expected to announce its next earnings results on Wednesday, March 4th.
According to Zacks, analysts expect that Idera Pharmaceuticals will report full-year earnings of ($1.51) per share for the current year, with EPS estimates ranging from ($1.60) to ($1.28). For the next fiscal year, analysts anticipate that the business will post earnings of ($1.25) per share, with EPS estimates ranging from ($1.79) to ($0.70). Zacks’ EPS averages are a mean average based on a survey of research analysts that that provide coverage for Idera Pharmaceuticals.
Idera Pharmaceuticals (NASDAQ:IDRA) last posted its quarterly earnings data on Wednesday, November 6th. The biotechnology company reported ($0.39) earnings per share for the quarter, topping the consensus estimate of ($0.46) by $0.07.
Shares of NASDAQ IDRA traded down $0.09 during trading hours on Tuesday, hitting $2.39. 74,000 shares of the company’s stock were exchanged, compared to its average volume of 275,491. Idera Pharmaceuticals has a 1-year low of $2.08 and a 1-year high of $8.95. The stock has a market capitalization of $76.15 million, a price-to-earnings ratio of -1.05 and a beta of 2.38. The company’s 50-day moving average price is $2.66 and its 200-day moving average price is $2.66.
In related news, major shareholder Invest Corp Pillar sold 100,000 shares of the stock in a transaction that occurred on Wednesday, November 6th. The stock was sold at an average price of $2.50, for a total transaction of $250,000.00. The transaction was disclosed in a document filed with the SEC, which is available through the SEC website. 3.46% of the stock is owned by corporate insiders.
A number of hedge funds and other institutional investors have recently added to or reduced their stakes in IDRA. GSA Capital Partners LLP boosted its position in Idera Pharmaceuticals by 50.2% in the 2nd quarter. GSA Capital Partners LLP now owns 98,309 shares of the biotechnology company’s stock valued at $262,000 after buying an additional 32,861 shares during the last quarter. Acadian Asset Management LLC boosted its position in Idera Pharmaceuticals by 273.5% in the 2nd quarter. Acadian Asset Management LLC now owns 165,044 shares of the biotechnology company’s stock valued at $440,000 after buying an additional 120,861 shares during the last quarter. Paloma Partners Management Co bought a new position in Idera Pharmaceuticals in the 2nd quarter valued at $228,000. Parametric Portfolio Associates LLC bought a new position in Idera Pharmaceuticals in the 2nd quarter valued at $44,000. Finally, Natixis boosted its position in Idera Pharmaceuticals by 61.7% in the 2nd quarter. Natixis now owns 743,618 shares of the biotechnology company’s stock valued at $1,985,000 after buying an additional 283,802 shares during the last quarter. Institutional investors and hedge funds own 36.12% of the company’s stock.
About Idera Pharmaceuticals
Idera Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of drugs for oncology in the United States. It offers Tilsotolimod, a synthetic phosphorothioate oligonucleotide that acts as a direct agonist of TLR9 to stimulate the immune systems and for treating solid tumors, metastatic melanoma, squamous cell carcinoma, and colorectal cancer.
See Also: Special Dividends
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Idera Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Idera Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.